Literature DB >> 30190993

Radiotherapy for liver tumors.

Florence K Keane1,1, Shyam K Tanguturi1,1, Andrew X Zhu2,2, Laura A Dawson3,3, Theodore S Hong4,4.   

Abstract

Many patients with primary hepatic malignancies present with advanced disease that is not suitable for surgical resection, orthotopic liver transplantation, or radiofrequency ablation. Outcomes are particularly dismal in patients with large, unresectable tumors and/or tumor venous thrombosis. Liver-directed radiotherapy, including stereotactic body radiotherapy (SBRT), is able to treat a variety of tumor sizes and tumors with venous involvement and has demonstrated excellent safety and control outcomes. SBRT should be considered a standard option in patients with early-stage hepatocellular carcinoma who are not candidates for surgical resection, orthotopic liver transplantation or radiofrequency ablation. SBRT should be strongly considered in patients with larger tumors and/or tumors with tumor venous thrombosis who have adequate liver function. Radiotherapy should remain a focus of hepatocellular carcinoma research.

Entities:  

Keywords:  hepatocellular carcinoma; proton therapy; radiation therapy; radiofrequency ablation; stereotactic body radiotherapy; transarterial chemoembolization; tumor venous thrombosis; unresectable hepatocellular carcinoma

Year:  2015        PMID: 30190993      PMCID: PMC6095425          DOI: 10.2217/hep.15.7

Source DB:  PubMed          Journal:  Hepat Oncol        ISSN: 2045-0923


  104 in total

1.  The use of active breathing control (ABC) to reduce margin for breathing motion.

Authors:  J W Wong; M B Sharpe; D A Jaffray; V R Kini; J M Robertson; J S Stromberg; A A Martinez
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-07-01       Impact factor: 7.038

Review 2.  Management of hepatocellular carcinoma with transarterial chemoembolization in the era of systemic targeted therapy.

Authors:  Riccardo Lencioni
Journal:  Crit Rev Oncol Hematol       Date:  2011-12-03       Impact factor: 6.312

3.  Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: a risk-stratification analysis.

Authors:  James E Goin; Riad Salem; Brian I Carr; Janet E Dancey; Michael C Soulen; Jean-Francois H Geschwind; Kathleen Goin; Mark Van Buskirk; Kenneth Thurston
Journal:  J Vasc Interv Radiol       Date:  2005-02       Impact factor: 3.464

4.  Changes in functional vascularity and cell number following x-irradiation of a murine carcinoma.

Authors:  J J Clement; C W Song; S H Levitt
Journal:  Int J Radiat Oncol Biol Phys       Date:  1976 Jul-Aug       Impact factor: 7.038

5.  Stereotactic body radiation therapy in recurrent hepatocellular carcinoma.

Authors:  Wen-Yen Huang; Yee-Min Jen; Meei-Shyuan Lee; Li-Ping Chang; Chang-Ming Chen; Kai-Hsiung Ko; Kuen-Tze Lin; Jang-Chun Lin; Hsing-Lung Chao; Chun-Shu Lin; Yu-Fu Su; Chao-Yueh Fan; Yao-Wen Chang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-02-17       Impact factor: 7.038

6.  Computer simulation of cytotoxic and vascular effects of radiosurgery in solid and necrotic brain metastases.

Authors:  M Kocher; H Treuer; J Voges; M Hoevels; V Sturm; R P Müller
Journal:  Radiother Oncol       Date:  2000-02       Impact factor: 6.280

Review 7.  Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials.

Authors:  Calogero Cammà; Filippo Schepis; Ambrogio Orlando; Maddalena Albanese; Lillian Shahied; Franco Trevisani; Pietro Andreone; Antonio Craxì; Mario Cottone
Journal:  Radiology       Date:  2002-07       Impact factor: 11.105

8.  Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients.

Authors:  H Blomgren; I Lax; I Näslund; R Svanström
Journal:  Acta Oncol       Date:  1995       Impact factor: 4.089

9.  Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.

Authors:  Stefan Zeuzem; Ira M Jacobson; Tolga Baykal; Rui T Marinho; Fred Poordad; Marc Bourlière; Mark S Sulkowski; Heiner Wedemeyer; Edward Tam; Paul Desmond; Donald M Jensen; Adrian M Di Bisceglie; Peter Varunok; Tarek Hassanein; Junyuan Xiong; Tami Pilot-Matias; Barbara DaSilva-Tillmann; Lois Larsen; Thomas Podsadecki; Barry Bernstein
Journal:  N Engl J Med       Date:  2014-04-10       Impact factor: 91.245

10.  Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.

Authors:  Nezam Afdhal; K Rajender Reddy; David R Nelson; Eric Lawitz; Stuart C Gordon; Eugene Schiff; Ronald Nahass; Reem Ghalib; Norman Gitlin; Robert Herring; Jacob Lalezari; Ziad H Younes; Paul J Pockros; Adrian M Di Bisceglie; Sanjeev Arora; G Mani Subramanian; Yanni Zhu; Hadas Dvory-Sobol; Jenny C Yang; Phillip S Pang; William T Symonds; John G McHutchison; Andrew J Muir; Mark Sulkowski; Paul Kwo
Journal:  N Engl J Med       Date:  2014-04-11       Impact factor: 91.245

View more
  3 in total

Review 1.  Liver-Directed Radiotherapy for Hepatocellular Carcinoma.

Authors:  Florence K Keane; Jennifer Y Wo; Andrew X Zhu; Theodore S Hong
Journal:  Liver Cancer       Date:  2016-05-10       Impact factor: 11.740

2.  Predictive Modeling of Survival and Toxicity in Patients With Hepatocellular Carcinoma After Radiotherapy.

Authors:  Ibrahim Chamseddine; Yejin Kim; Brian De; Issam El Naqa; Dan G Duda; John Wolfgang; Jennifer Pursley; Harald Paganetti; Jennifer Wo; Theodore Hong; Eugene J Koay; Clemens Grassberger
Journal:  JCO Clin Cancer Inform       Date:  2022-02

3.  Impact of potentially variable RBE in liver proton therapy.

Authors:  Yizheng Chen; Clemens Grassberger; Junli Li; Theodore S Hong; Harald Paganetti
Journal:  Phys Med Biol       Date:  2018-09-21       Impact factor: 3.609

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.